Compare CF Industries Holdings, Inc. (CF) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CF Industries Holdings, Inc. vs TG Therapeutics Inc — how do they compare? CF Industries Holdings, Inc. trades at $120.48 (market cap $17.83B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: CF Industries Holdings, Inc. is far larger — about 2.3× TG Therapeutics Inc's market cap, and CF Industries Holdings, Inc. pays a 2.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CF | TGTX | |
|---|---|---|
Market Cap | $17.83B | $7.64B |
Sector | Basic Materials | Health |
52-Week High | $137.55 | $59.06 |
52-Week Low | $76.08 | $26.94 |
Enterprise Value | $18.96B | $7.84B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CF Industries trades at $119.33, down 1.8% with bearish technical signals. The stock shows strong fundamentals with a P/E of 8.74 and ROE of 39.19%, though Q2 2026 earnings missed expectations. Revenue grew to $7.08B in 2025 with net income of $1.46B. Analyst consensus remains positive with 51% buy ratings and a $119.60 price target. Recent institutional activity shows mixed positioning with some firms increasing stakes while others reduced holdings.
The outlook remains cautiously optimistic given strong nitrogen market fundamentals and improving cash flow trends. Key risks include production volatility and commodity price sensitivity. With current pricing near analyst targets, the stock offers value but requires monitoring of operational execution and global fertilizer demand trends.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CF Industries Holdings, Inc.
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
